Nature's Sunshine Products Inc

Nature's Sunshine Products Inc(NATR)股票分析

$12.840

+0.819 (+6.38%)收盘时

Loading chart…
最高
12.940
开盘
12.340
成交量加权均价
12.70
成交量
123.14K
市值
281.51M
最低
12.320
成交额
1.56M
企业价值/息税折旧摊销前利润(TTM)
3.91

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.

AI 分析 of Nature's Sunshine Products Inc (NATR)

持有

Nature's Sunshine Products Inc (NATR) is currently trading at $12.02, significantly below its 52-week high of $28.14, indicating potential for recovery. However, the stock has a low RSI of 28.072, suggesting it is oversold, but the recent earnings miss and lowered guidance raise concerns about future performance. The forward P/E ratio is 8.87, which is attractive, but the net income has been inconsistent, with a recent drop to $3.54 million in Q2 2026. The main risk is the insider selling, which has increased by 161.97% over the last month, indicating lack of confidence among insiders. Therefore, while there is potential for upside, the current market sentiment and risks suggest holding rather than buying at this time.

估值指标

Nature's Sunshine Products Inc(NATR)当前预期市盈率为 8.71,5 年平均预期市盈率为 12.41。

预期市盈率

合理
5 年均值 P/E
12.41
当前P/E
8.71
高估
57.86
低估
-33.04

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.44
当前EV/EBITDA
3.91
高估
9.12
低估
3.77

预期市销率

低估
5 年均值 P/S
0.62
当前P/S
0.41
高估
0.76
低估
0.48

Alphio AI 对 NATR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NATR

$16.58

情景价格

基

基准

基准 · 50%NATR

$16.06

情景价格

悲

悲观

悲观 · 25%NATR

$14.23

情景价格

持有 NATR 的大户

S

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

+ 持有NATR

-15.12%

3个月收益率

事件时间线

2026-11-04 (ET)

17:30:00

Nature's Sunshine Reports Q3 Revenue of $116.6M

17:30:00

Nature's Sunshine Cuts FY26 Adjusted EBITDA Outlook to $44M-$48M

2026-08-06 (ET)

18:30:00

Nature's Sunshine Appoints Ruth Perkins as CFO

2026-05-07 (ET)

17:50:00

Reiterates FY26 Revenue View of $500M-$515M

17:50:00

Company Reports Q1 Revenue of $122.9M

资讯

NATR 常见问题 —— 由 Alphio AI 解答

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk. It operates in the Consumer Non-Cyclicals sector (PHARMACEUTICAL PREPARATIONS industry).

Nature's Sunshine Products Inc (NATR) is currently trading at $12.02, significantly below its 52-week high of $28.14, indicating potential for recovery. However, the stock has a low RSI of 28.072, suggesting it is oversold, but the recent earnings miss and lowered guidance raise concerns about future performance. The forward P/E ratio is 8.87, which is attractive, but the net income has been inconsistent, with a recent drop to $3.54 million in Q2 2026. The main risk is the insider selling, which has increased by 161.97% over the last month, indicating lack of confidence among insiders. Therefore, while there is potential for upside, the current market sentiment and risks suggest holding rather than buying at this time.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易